Immunic (IMUX) Competitors

$12.62 -0.33 (-2.56%)

Closing price 03:59 PM Eastern

Extended Trading

$12.66 +0.04 (+0.29%)

As of 04:06 PM Eastern

IMUX vs. PROK, TECX, EIKN, ALLO, and CADL

Should you buy Immunic stock or one of its competitors? MarketBeat compares Immunic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunic include ProKidney (PROK), Tectonic Therapeutic (TECX), EIKN (EIKN), Allogene Therapeutics (ALLO), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Immunic compare to ProKidney?

Immunic (NASDAQ:IMUX) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Immunic has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Immunic has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-1,197.81%	-264.95%
ProKidney	-7,725.20%	N/A	-18.83%

Immunic presently has a consensus price target of $50.86, indicating a potential upside of 303.02%. ProKidney has a consensus price target of $7.40, indicating a potential upside of 331.49%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Immunic had 4 more articles in the media than ProKidney. MarketBeat recorded 8 mentions for Immunic and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.72 beat Immunic's score of 0.26 indicating that ProKidney is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProKidney has higher revenue and earnings than Immunic. ProKidney is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
ProKidney	$890K	581.79	-$68.99M	-$0.52	N/A

51.8% of Immunic shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 14.0% of Immunic shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ProKidney beats Immunic on 9 of the 16 factors compared between the two stocks.

How does Immunic compare to Tectonic Therapeutic?

Immunic (NASDAQ:IMUX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Immunic has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.27, indicating that its share price is 227% more volatile than the broader market.

Tectonic Therapeutic's return on equity of -32.33% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-1,197.81%	-264.95%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Immunic presently has a consensus price target of $50.86, indicating a potential upside of 303.02%. Tectonic Therapeutic has a consensus price target of $80.57, indicating a potential upside of 170.60%. Given Immunic's stronger consensus rating and higher possible upside, equities analysts plainly believe Immunic is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Immunic had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Immunic and 4 mentions for Tectonic Therapeutic. Immunic's average media sentiment score of 0.26 beat Tectonic Therapeutic's score of 0.13 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

51.8% of Immunic shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 14.0% of Immunic shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic beats Immunic on 7 of the 13 factors compared between the two stocks.

How does Immunic compare to EIKN?

EIKN (NASDAQ:EIKN) and Immunic (NASDAQ:IMUX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

51.8% of Immunic shares are held by institutional investors. 14.0% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EIKN	N/A	N/A	N/A	N/A	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

EIKN's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EIKN	N/A	N/A	N/A
Immunic	N/A	-1,197.81%	-264.95%

In the previous week, Immunic had 2 more articles in the media than EIKN. MarketBeat recorded 8 mentions for Immunic and 6 mentions for EIKN. Immunic's average media sentiment score of 0.26 beat EIKN's score of -0.46 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EIKN	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

EIKN currently has a consensus price target of $25.20, suggesting a potential upside of 90.76%. Immunic has a consensus price target of $50.86, suggesting a potential upside of 303.02%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than EIKN.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Immunic beats EIKN on 8 of the 10 factors compared between the two stocks.

How does Immunic compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Allogene Therapeutics' return on equity of -57.07% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-57.07%	-41.63%
Immunic	N/A	-1,197.81%	-264.95%

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 14.0% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Immunic has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Allogene Therapeutics had 3 more articles in the media than Immunic. MarketBeat recorded 11 mentions for Allogene Therapeutics and 8 mentions for Immunic. Allogene Therapeutics' average media sentiment score of 0.67 beat Immunic's score of 0.26 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allogene Therapeutics currently has a consensus price target of $8.07, suggesting a potential upside of 276.22%. Immunic has a consensus price target of $50.86, suggesting a potential upside of 303.02%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Allogene Therapeutics and Immunic tied by winning 7 of the 14 factors compared between the two stocks.

How does Immunic compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Candel Therapeutics' return on equity of -51.44% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-51.44%	-36.31%
Immunic	N/A	-1,197.81%	-264.95%

In the previous week, Immunic had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Immunic and 7 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.57 beat Immunic's score of 0.26 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics has a beta of -0.59, indicating that its stock price is 159% less volatile than the broader market. Comparatively, Immunic has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Candel Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 102.66%. Immunic has a consensus price target of $50.86, suggesting a potential upside of 303.02%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 14.0% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.71	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Summary

Immunic beats Candel Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.90M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.80	18.81	20.87	25.61
Price / Sales	N/A	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	-22.94	6.75	9.86	6.71
Net Income	-$97.17M	$24.11M	$3.55B	$333.77M
7 Day Performance	7.40%	0.11%	-0.26%	0.40%
1 Month Performance	6.94%	0.87%	1.39%	4.03%
1 Year Performance	29.13%	78.18%	41.07%	36.33%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	3.6956 of 5 stars	$12.62 -2.6%	$50.86 +303.0%	+30.8%	$171.90M	N/A	N/A	70	Earnings Report Upcoming Earnings Analyst Forecast Short Interest Decrease
PROK ProKidney	1.8481 of 5 stars	$1.88 -2.6%	$7.40 +293.6%	+101.5%	$567.60M	$893K	N/A	3
TECX Tectonic Therapeutic	2.2353 of 5 stars	$29.65 +2.0%	$80.57 +171.7%	+42.7%	$558.90M	N/A	N/A	120	Earnings Report
EIKN EIKN	N/A	$10.27 +6.1%	$25.60 +149.3%	N/A	$556.01M	N/A	N/A	384	News Coverage Earnings Report Analyst Forecast
ALLO Allogene Therapeutics	3.4841 of 5 stars	$2.26 +5.1%	$8.44 +273.4%	+106.2%	$553.29M	$20K	N/A	310	Trending News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. PROK, TECX, EIKN, ALLO, and CADL

How does Immunic compare to ProKidney?

Summary

How does Immunic compare to Tectonic Therapeutic?

Summary

How does Immunic compare to EIKN?

Summary

How does Immunic compare to Allogene Therapeutics?

Summary

How does Immunic compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. PROK, TECX, EIKN, ALLO, and CADL

How does Immunic compare to ProKidney?

Which has more volatility & risk, IMUX or PROK?

Is IMUX or PROK more profitable?

Do analysts prefer IMUX or PROK?

Does the media refer more to IMUX or PROK?

Which has better valuation and earnings, IMUX or PROK?

Do institutionals & insiders have more ownership in IMUX or PROK?

Summary

How does Immunic compare to Tectonic Therapeutic?

Which has more risk & volatility, IMUX or TECX?

Is IMUX or TECX more profitable?

Do analysts prefer IMUX or TECX?

Does the media prefer IMUX or TECX?

Which has stronger valuation & earnings, IMUX or TECX?

Do insiders and institutionals have more ownership in IMUX or TECX?

Summary

How does Immunic compare to EIKN?

Do institutionals and insiders have more ownership in EIKN or IMUX?

Which has preferable earnings and valuation, EIKN or IMUX?

Is EIKN or IMUX more profitable?

Does the media favor EIKN or IMUX?

Do analysts recommend EIKN or IMUX?

Summary

How does Immunic compare to Allogene Therapeutics?

Which has better earnings & valuation, ALLO or IMUX?

Is ALLO or IMUX more profitable?

Do insiders & institutionals have more ownership in ALLO or IMUX?

Which has more volatility and risk, ALLO or IMUX?

Does the media favor ALLO or IMUX?

Do analysts prefer ALLO or IMUX?

Summary

How does Immunic compare to Candel Therapeutics?

Is CADL or IMUX more profitable?

Does the media favor CADL or IMUX?

Which has more volatility and risk, CADL or IMUX?

Do analysts prefer CADL or IMUX?

Do insiders & institutionals have more ownership in CADL or IMUX?

Which has better earnings & valuation, CADL or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools